We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 407

Sixth Circuit Vacates Class Settlement, Finding that Sealed Documents Prevented Objectors from Assessing Settlement’s Fairness
  • Baker & Hostetler LLP
  • USA
  • September 14 2016

This summer, the Sixth Circuit rejected class action litigants’ filing of the bulk of their class settlement documents under seal. Shane Grp., Inc. v


Third Circuit Sets Framework for Numerosity Requirement
  • Baker & Hostetler LLP
  • USA
  • September 14 2016

In an opinion issued yesterday, the Third Circuit provided a framework for analyzing the oft-overlooked numerosity requirement of Rule 23(a)(1). In re


Health Law Update - August 25, 2016
  • Baker & Hostetler LLP
  • USA
  • August 25 2016

Welcome to this week's edition of the Health Law Update. In This Issue: A Tale of Two Escobars: Federal Courts Begin Grappling with Opposing Views of


Unanimous FTC Finds LabMD’s Data Security Practices Violated Section 5 of the FTC Act
  • Baker & Hostetler LLP
  • USA
  • August 18 2016

On July 29, 2016, a unanimous Federal Trade Commission (“FTC” or “Commission”) issued its Opinion and Final Order reversing the decision of an


2016 Mid-Year Securities Litigation and Enforcement Highlights
  • Baker & Hostetler LLP
  • Ireland, USA
  • July 29 2016

Welcome to the 2016 Mid-Year Report From the BakerHostetler Securities Litigation and Regulatory Enforcement Practice Team. The purpose is to provide


Federal Circuit Helps Clarify What Constitutes a Commercial Sale under Pfaff
  • Baker & Hostetler LLP
  • USA
  • July 18 2016

In The Medicines Co. v. Hospira Inc., Appeal No. 2014-1469 (Fed. Cir. July 11, 2016), the Federal Circuit issued a unanimous en banc decision ruling


Federal Circuit Provides Additional Guidance in Reversing Holding of Patent-Ineligibility of Biotech Invention
  • Baker & Hostetler LLP
  • USA
  • July 7 2016

Although it is not yet a bright line, the Federal Circuit has considerably decreased the fuzziness of the distinction between patent-eligible and


Federal Circuit Confirms That the BPCIA Always Requires Post-Licensure Notice
  • Baker & Hostetler LLP
  • USA
  • July 6 2016

The Federal Circuit answered one of the questions left open by its July 27, 2015, decision in Amgen Inc. v. Sandoz Inc. (Appeal No. 2015-1499):


No Longer Implied: Supreme Court Expressly Recognizes Implied Certification as a Theory of Liability Under the False Claims Act
  • Baker & Hostetler LLP
  • USA
  • June 17 2016

Court Rejects the First Circuit's "Expansive View" of the Theory by Articulating "Rigorous" Standards of Materiality. Yesterday, the U.S. Supreme


Differences in Medical Opinions: Not Enough to Prove FCA Liability
  • Baker & Hostetler LLP
  • USA
  • May 19 2016

In a $200 million False Claims Act (FCA) litigation with certain twists and turns, the U.S. District Court for the Northern District of Alabama